Use for one year and three years was associated with a 1.5- and 2.4-fold increase in the risk of stomach cancer, respectively.
Proton pump inhibitors (PPIs), a popular class of heartburn drugs, are linked to stomach cancer, a recent review found.
The review indicates that prolonged use of PPIs – exceeding three months – “is significantly associated with an elevated risk of cancer,” while shorter-term usage “appears to pose a comparatively lower risk,” the authors wrote.
PPIs are potent drugs that lower stomach acidity. They work by binding irreversibly to proton pumps – proteins in the stomach that release protons, a component of stomach acid. This action prevents the secretion of protons. Continue reading